The company's first mRNA Japanese encephalitis vaccine, GBP560, entered Phase 1/2 trials in Australia and New Zealand. It is distinct from its existing non-mRNA vaccines.
South KoreaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
473 matching companiesShowing 193–216 / 473
A historical partner page describes Stemirna's mRNA vaccine and nanolipid/polymer delivery R&D. The company's website was inaccessible during this review; current operations and clinical status remain unverified.
Mainland ChinaFull profile →
Yunxin Zhili is a Hangzhou-based service provider supporting process development, manufacturing, and CMC activities for advanced therapies. Its official materials describe plasmid and mRNA services spanning sequence and template preparation, RNA production, purification, LNP formulation, and testing, with targeted LNP development also listed. Manufacturing grade, project scale, timelines, and regulatory suitability require project-specific confirmation.
Mainland ChinaFull profile →
Levostar Biotech, based in Suzhou, supports nucleic acid and cell and gene therapy projects with plasmid services, RNA synthesis and delivery development, and analytical testing. Its mRNA offering includes sequence design, template construction, RNA production, and LNP formulation. The targeted LNP platform describes antibody conjugation and particle characterization. Manufacturing grade and suitability for a clinical regulatory submission must be confirmed for each project.
Mainland ChinaFull profile →
ProtaGene offers Protein structure, impurities, potency and analytical comparability. Services should be matched to the intended study and assay requirements.
Germany / United StatesFull profile →
BioAgilytix offers Large-molecule PK, ADA, neutralizing antibodies, biomarkers and CMC analytics. Services should be matched to the intended study and assay requirements.
United States / GermanyFull profile →
Combines formulation development, clinical pharmacology, and manufacturing, including selection of solubility enhancement technologies, pediatric palatability improvement, and formulation development for multiple administration routes.
United KingdomFull profile →
Connects spray-dried ASD and particle engineering with oral drug products, offering blending, dry granulation, tableting, coating, and encapsulation from formulation assessment through clinical batches.
PortugalFull profile →
Offers drug product CDMO services from formulation design and clinical materials through commercial manufacturing and packaging, including complex oral solids, injectables, and ophthalmic products.
SwitzerlandFull profile →
A technology-focused CDMO specializing in small-molecule oral dosage forms, with disclosed formulation and analytical development for taste masking, tailored release, pediatric, and patient-friendly products.
United StatesFull profile →
Offers oral, nasal, pulmonary, and early-stage sterile formulation development, from feasibility and prototypes through scale-up and clinical manufacturing, addressing low solubility and stability challenges.
United KingdomFull profile →
SGS offers Protein characterization, potency, GMP release, stability and bioanalysis. Services should be matched to the intended study and assay requirements.
Switzerland / United States / Canada / Mainland China / United Kingdom / GermanyFull profile →
The unified Bend Bioscience brand brings together the former CoreRx, Societal, and Bend businesses, offering oral solids, oral liquids, ASD, and development from preformulation through process scale-up.
United StatesFull profile →
Offers formulation development across a U.S., U.K., and Indian network, with publicly listed nanosuspension, microemulsion, ASD, oral solid, and sterile injectable capabilities.
IndiaFull profile →
The development business supports early formulation through registration-batch scale-up and regulatory submissions. Injectable development at Leiden and other sites connects with the group's manufacturing network.
FranceFull profile →
Discloses development from preformulation through final formulation and analytical methods, with expanded bioavailability enhancement for poorly soluble drugs and clinical trial support.
GermanyFull profile →
The group has both proprietary drug and CDMO businesses. Publicly disclosed CDMO services cover development and manufacturing of complex oral solids, liquids, semisolids, biologics, and sterile injectables.
Taiwan, ChinaFull profile →
Biologics formulation and optimization services include computational analysis, excipient screening, stability, packaging, and high-concentration and in-use studies. The CDMO business is part of the FUJIFILM group.
JapanFull profile →
CMIC's drug product CDMO services cover preformulation, process and analytical development, clinical materials, and commercial supply. Official materials identify CMIC CDMO as part of the Dai Nippon Printing group.
JapanFull profile →
Offers clinical and commercial contract manufacturing for oral solids and injectables, and describes CMC development spanning process and formulation design, analytical work, and regulatory submissions.
JapanFull profile →
The group website lists TPD as a CRO service. Custom offerings explicitly cover target engagement, modulation, and degradation, plus custom proteins, cell lines, and assay development.
LuxembourgFull profile →
Oral dosage development combines spray-dried ASD, HME, particle size reduction, lipid formulations, and controlled release, spanning preclinical and clinical supply through commercial scale-up.
United StatesFull profile →
LTS completed its acquisition of the former Renaissance Lakewood business in November 2025 and integrated it into the Nasal & Sterile Drug Products division, offering nasal spray and sterile dosage form R&D and manufacturing.
United StatesFull profile →
Canadian contract development and manufacturing services include formulation development, comprehensive physicochemical characterization, development of simple and complex sterile formulations, and aseptic fill-finish.
CanadaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.